Will sustained biological therapy improve long‑term outcome in inflammatory bowel disease?

Pär Myrelid¹, Michael Eberhardson^{2

3}

Affiliations

¹ Department of Surgery, Linköping University Hospital and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. par.myrelid@liu.se
² Department of Gastroenterology and Hepatology, Linköping University Hospital and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
³ Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Free article

Editorial

Pär Myrelid et al. Pol Arch Intern Med. 2022.

Free article

. 2022 Aug 22;132(7-8):16309.

doi: 10.20452/pamw.16309. Epub 2022 Aug 22.

Pär Myrelid¹, Michael Eberhardson^{2

3}

¹ Department of Surgery, Linköping University Hospital and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. par.myrelid@liu.se
² Department of Gastroenterology and Hepatology, Linköping University Hospital and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
³ Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

No abstract available

Comment on

Biologic treatment of inflammatory bowel disease in Poland, 2012-2020: nationwide data.
Kucha P, Zagórowicz E, Walkiewicz D, Perwieniec J, Maluchnik M, Wieszczy P, Reguła J. Kucha P, et al. Pol Arch Intern Med. 2022 Aug 22;132(7-8):16287. doi: 10.20452/pamw.16287. Epub 2022 Jul 4. Pol Arch Intern Med. 2022. PMID: 35785917